Results 141 to 150 of about 132,704 (355)

Persistent Facial Nodules in an Elderly Patient

JEADV Clinical Practice, EarlyView.
Qian Ding, Qin‐Si Liu, Heng‐Guang Zhao   +2 more
wiley   +1 more source

The burden of itch: Evaluating pruritus in children with burn injuries

Indian Journal of Burns
Background: Chronic pruritus in pediatric burn patients is a distressing and often overlooked complication that can significantly impact quality of life.
Dujanah Bhatti, Nur Ul Ain, Muzna Mehmood, Ankur Pandya, Husnain Khan   +4 more
doaj   +1 more source

Assessing the Effect of Adalimumab in Granuloma Annulare: A Case Series and Literature Review

JEADV Clinical Practice, EarlyView.
ABSTRACT Granuloma annulare (GA) is a benign granulomatous skin disorder for which standardized treatment guidelines are lacking due to limited evidence. Adalimumab, a TNF‐α inhibitor, shows promise as a therapeutic option due to its potential to disrupt GA granulomas.
Adriana Caixinha Valorenzos, Line Kibsgaard, Trine Bertelsen   +2 more
wiley   +1 more source

Successful Use of Bimekizumab in Refractory Acute Generalised Exanthematous Pustulosis Triggered by Amoxicillin‐Clavulanate

JEADV Clinical Practice, EarlyView.
ABSTRACT Acute generalised exanthematous pustulosis (AGEP) is a rare, acute neutrophilic dermatosis most commonly triggered by drugs, which typically resolves within 2 weeks following withdrawal of the causative agent. Topical and systemic corticosteroids remain the standard treatment.
Alexandra Junge, Charlotte Vogel, Theresa Hempel, Basil Signer, Nikhil Yawalkar, Kristine Heidemeyer   +5 more
wiley   +1 more source

Uraemic pruritus [PDF]

Nephrology Dialysis Transplantation, 1999
I F, Schwartz, A, Iaina
openaire   +2 more sources

Efficacy of Lebrikizumab in Patients With Severe Atopic Dermatitis Who Would be Eligible for Treatment Based on the South Korean Reimbursement Criteria

JEADV Clinical Practice, EarlyView.
ABSTRACT Background Lebrikizumab is approved to treat patients with moderate‐to‐severe atopic dermatitis (AD). Objectives This study evaluated the 16‐week efficacy outcomes of lebrikizumab in adults and adolescents with severe AD in ADvocate trials who would be eligible for treatment based on South Korean reimbursement‐like criteria. Methods This was a
Chong Hyun Won, Chun Wook Park, Jiyoung Ahn, Joo Yeon Ko, Sang Hyun Cho, Yang Won Lee, Joo Hee Lee, Khai Jing Ng, Min Young Hong, Jinglin Zhong, Martin Dossenbach, Sang Wook Son   +11 more
wiley   +1 more source

Treatment for Refractory Pruritus Using Oral Aprepitant [PDF]

, 2016
Joon Huh, Young-In Jeong, Kwang-Hyun Choi, Hyang-Joon Park, Mihn‐Sook Jue   +4 more
openalex   +1 more source

Exploring content and psychometric validity of newly developed assessment tools for itch and skin pain in atopic dermatitis. [PDF]

, 2019
BackgroundAtopic dermatitis (AD) is a common skin disorder characterized by chronic inflammation, altered skin barrier function, and inflammatory cell skin infiltration that decreases health-related quality of life (HRQoL).
Abetz-Webb, Linda, DeLozier, Amy M, Eichenfield, Lawrence F, Gable, Jonathon C, Griffiths, Philip C, Hill, Jennifer N, Hudgens, Stacie, Newton, Louise, Paik, Jim, Silverberg, Jonathan I, Symonds, Tara, Wyrwich, Kathleen W   +11 more
core  

Vulvar pruritus [PDF]

BMJ Case Reports, 2020
Catarina Estevinho, Elisa Soares, Ana Portela Carvalho, Fernanda Costa   +3 more
openaire   +2 more sources

Juvenile Mycosis Fungoides: A Multicenter Retrospective Italian Study

JEADV Clinical Practice, EarlyView.
This multicenter retrospective study included 29 juvenile mycosis fungoides (JMF) patients from five Italian centres with confirmed histopathological diagnosis. most often presents with hypopigmented/classic variants and CD8+ phenotype. Early‐onset cases ( < 14 years) show better long‐term outcomes.
Andrea Michelerio, Gabriele Roccuzzo, Iria Neri, Alessandro Pileri, Alessandro Svizzero, Maria Beatrice De Felici Del Giudice, Vieri Grandi, Pietro Quaglino, Valeria Brazzelli   +8 more
wiley   +1 more source